Nektar(US:NKTR)2025-12-16 13:00Efficacy Results - The Phase 2b REZOLVE-AA study evaluated rezpegaldesleukin (REZPEG) for alopecia areata [1, 19] - The study achieved statistical significance for both treatment arms after excluding 4 patients with major study eligibility violations [36] - The mean percentage change in SALT score from baseline to week 36 was -30% in the REZPEG arms versus -6% in the placebo arm (p<0.05), after excluding 4 patients with major study eligibility violations [92] - 42% of REZPEG-treated patients achieved a best reduction in SALT score of 30% or greater [47] - 36% of REZPEG-treated patients achieved a best reduction in SALT score of 50% or greater [47] - 17% of REZPEG-treated patients achieved a best reduction in SALT score of 75% or greater [47] Safety and Tolerability - The study showed a consistent safety profile with previously reported studies, with nearly all adverse events (AEs) being mild to moderate in severity and self-resolved [31] - The discontinuation rate due to AEs was low at 1.4% for REZPEG-exposed patients [31] - The placebo-adjusted injection site reaction (ISR) rate was consistent with prior studies, with 87% being mild in severity [31] Market and Strategic Implications - The data supports a first-in-class Treg mechanism of action with fast onset of action in moderate-to-severe patients [9] - 54% of physicians report they would try patients on alternate therapies for AA before prescribing JAKi [10] - G7 market size for Alopecia Areata is projected to reach $4 billion by 2033 [7]